Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Offering & Application to List on Nasdaq

26 Apr 2018 07:00

RNS Number : 1577M
Mereo BioPharma Group plc
26 April 2018
 

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014).UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN

 

 

Mereo BioPharma Group plc

("Mereo" or the "Company" or the "Group")

 

Mereo BioPharma Update on Global Offering and Application to List its ADSs on the Nasdaq Global Market

 

London, April 26, 2018 - Mereo BioPharma Group plc (AIM: MPH), a multi-asset biopharmaceutical company focused on the acquisition, development and commercialisation of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases, announces today that the Company has withdrawn the global offering and postponed its proposed listing of its American Depositary Shares ("ADSs") on the Nasdaq Global Market that was previously announced on April 9, 2018. The Company believes that current market conditions are not conducive for an offering on terms that would be in the best interests of its shareholders.

 

The Company remains well funded, with a net cash, short-term deposits and short-term investment balance of £52.5 million at December 31, 2017. This provides a strong cash runway to deliver the next key clinical programme milestones and corporate objectives.

 

The development of the Company's clinical assets remains on track. In December 2017, the Company reported positive top-line data from its completed phase 2 dose-ranging clinical trial for BCT-197 for the treatment of acute exacerbations of chronic obstructive pulmonary disease and we are subsequently making good progress in partnering discussions. In March 2018, the Company reported positive top-line data from its phase 2b dose-ranging clinical trial for BGS-649, a once a week oral treatment for hypogonadotropic hypogonadism (HH) in obese men. The development of the Company's two other clinical assets, BPS-804, a novel antibody the Company is developing as a treatment for osteogenesis imperfecta (OI), and AZD-9668, for patients with severe AATD, also remains on track.

 

Dr Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma Group plc commented:

 

"We received positive feedback and strong levels of institutional interest during the offering process. However, challenging stock market conditions have led our Board to take the decision to withdraw our global offering and postpone our proposed listing of ADSs on Nasdaq in the interests of our existing shareholders.

 

 We are making good progress in the clinic and have reported positive data from both our BCT-197 and BGS-649 clinical programmes over the last few months. Subsequently we are also progressing BCT-197 partnering discussions. We remain well funded and are confident in the future development and potential value of our pipeline."

 

 

For Further Enquiries:

 

Mereo BioPharma Group plc

+44 (0)333 023 7319

Denise Scots-Knight, Chief Executive Officer

Richard Jones, Chief Financial Officer

Nominated Adviser and Joint Broker

Cantor Fitzgerald Europe

+44 (0)20 7894 7000

Phil Davies

Will Goode

Joint Broker

RBC Capital Markets

+44 (0)20 7653 4000

Rupert Walford

Laura White

UK Public Relations Advisor to Mereo Biopharma

FTI Consulting

+44 (0)20 3727 1000

Ben Atwell

Simon Conway

Brett Pollard

US Public Relations Advisor to Mereo Biopharma

Burns McClellan

 +01 (0) 212 213 0006

Lisa Burns

Steven Klass

 

 

About Mereo

Mereo is a multi-asset biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases. The portfolio consists of four clinical-stage product candidates, each of which were acquired from large pharmaceutical companies: BPS-804 for the treatment of osteogenesis imperfecta; AZD-9668 for the treatment of severe alpha-1 antitrypsin deficiency; BCT-197 for the treatment of acute exacerbations of chronic obstructive pulmonary disease ("AECOPD"); and BGS-649 for the treatment of hypogonadotropic hypogonadism ("HH") in obese men. Each of the Company's product candidates has generated positive clinical data for Mereo's target indication or in a related indication. The Company's strategy is to selectively acquire product candidates that have already received significant investment from pharmaceutical companies and that have substantial preclinical, clinical and manufacturing data packages. Since inception the Company has commenced large, randomized, placebo-controlled Phase 2 clinical trials for three of the product candidates and announced positive top-line results from its Phase 2 clinical trial of BCT-197 as an acute therapy for patients with AECOPD in December 2017 and positive top-line data from its Phase 2b dose-ranging study with BGS-649 for the treatment of HH.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEEAFLSALXPEAF
Date   Source Headline
15th Dec 20206:22 pmRNSAIM Delisting
30th Nov 20207:00 amRNSKey Dates for AIM Delisting
23rd Nov 202012:00 pmRNSMereo appoints Suba Krishnan
16th Nov 202012:00 pmRNSVirtual R&D Day
11th Nov 20207:00 amRNSCancellation of AIM admission
10th Nov 202012:00 pmRNSStifel 2020 Virtual Healthcare Conference
20th Oct 202012:00 pmRNSAppointments of CFO and SVP
19th Oct 202012:00 pmRNSTIGIT IND FDA Clearance
12th Oct 20201:44 pmRNSPDMR Notification
9th Oct 20204:05 pmRNSDirector/PDMR Shareholding
7th Oct 202012:00 pmRNSRegistration Statement Filed with US SEC
29th Sep 202012:00 pmRNSInterim Results for 6 months ended June 30, 2020
28th Sep 20203:21 pmRNSResult of General Meeting
28th Sep 202012:00 pmRNSChanges to Board of Directors
24th Sep 202012:00 pmRNSFDA Rare Pediatric Disease Designation
16th Sep 20201:00 pmRNSNotice of Interim Results
4th Sep 20207:00 amRNSNotice of General Meeting
25th Aug 202012:00 pmRNSInitiation of COVID-19 Respiratory Disease Trial
14th Aug 20207:00 amRNSPDMR Notification
13th Aug 20207:00 amRNSNotification of PDMR Dealing
6th Aug 20207:00 amRNSAppointment of Nominated Adviser & Broker
5th Aug 20207:00 amRNSDirector Dealing
6th Jul 20203:59 pmRNSHolding(s) in Company
6th Jul 20209:34 amRNSBlock Listing Application
30th Jun 20201:39 pmRNSResult of General Meeting
30th Jun 202012:00 pmRNSCSO and SVP appointments
29th Jun 20203:56 pmRNSResult of Annual General Meeting
22nd Jun 20204:33 pmRNSHolding(s) in Company
22nd Jun 202011:06 amRNSSecond Price Monitoring Extn
22nd Jun 202011:00 amRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSFinal Results for the year ended December 31, 2019
11th Jun 20204:41 pmRNSSecond Price Monitoring Extn
11th Jun 20204:36 pmRNSPrice Monitoring Extension
10th Jun 20205:30 pmRNSHolding(s) in Company
9th Jun 20204:45 pmRNSNotice of General Meeting
8th Jun 20205:56 pmRNSHolding(s) in Company
8th Jun 20205:18 pmRNSHolding(s) in Company
8th Jun 20203:20 pmRNSHolding(s) in Company
5th Jun 20203:55 pmRNSHolding(s) in Company
5th Jun 202012:49 pmRNSHolding(s) in Company
4th Jun 20202:05 pmRNSSecond Price Monitoring Extn
4th Jun 20202:00 pmRNSPrice Monitoring Extension
4th Jun 20207:00 amRNSCompletion of $70 Million Private Placement
3rd Jun 20209:05 amRNSSecond Price Monitoring Extn
3rd Jun 20209:00 amRNSPrice Monitoring Extension
27th May 202012:00 pmRNSNotice of Annual General Meeting
22nd May 202012:00 pmRNSAnnual General Meeting
21st May 20204:18 pmRNSHolding(s) in Company
27th Mar 202012:00 pmRNSBusiness Update and Directorate Change
6th Mar 20207:00 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.